NLNK NewLink Genetics Corporation

14.34
-0.90  -6%
Previous Close 15.24
Open 15.20
Price To book 3.89
Market Cap 419.09M
Shares 29,225,000
Volume 753,248
Short Ratio 5.64
Av. Daily Volume 718,973

SEC filingsSee all SEC filings

  1. 8-K - Current report 17853509
  2. 8-K - Current report 17852569
  3. 8-K - Current report 17851633
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17817633
  5. 8-K - Current report 17811983

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2H 2017.
Indoximod + chemotherapy
Acute Myeloid Leukemia (AML)
Phase 1/2 data to be presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 pivotal China trial initiation announced April 21, 2017.
BGB-A317
Hodgkin lymphoma
Phase 2 poster presentation due at ASCO June 5, 2017. Abstract 3066.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase 2 interim analysis released at AACR meeting April 4, 2017.
Indoximod in combination with pembrolizumab
Melanoma - cancer
Phase 2 data due 2H 2017.
Indoximod + temozolomide
Glioblastoma multiforme cancer
Phase 2 data due 2H 2017.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Enrolling
Indoximod +Tergenpumatucel-L
Non-small cell lung cancer (NSCLC)
Phase 2 data due 2017.
Indoximod + taxane
Cancer - breast

Latest News

  1. Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer
  2. Biotech Stocks: Is ASCO Much Ado About Nothing?
  3. Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
  4. Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
  5. Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK
  6. ETFs with exposure to NewLink Genetics Corp. : May 11, 2017
  7. NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  8. NewLink Genetics to Participate in Upcoming Investor Conferences
  9. 3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month
  10. NewLink reports 1Q loss
  11. NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
  12. Investor Network: Newlink Genetics Corporation to Host Earnings Call
  13. Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharmaceuticals Holdings, Inc., Lion Biotechnologies, Inc., NewLink Genetics Corporation, Power Solutions International, Inc., Walter Investment Management Corp. and XBIOTECH INC.
  14. Vaunted Ebola Vaccine Faces Questions
  15. NewLink Genetics Corp. – Value Analysis (NASDAQ:NLNK) : April 21, 2017
  16. Should Gilead Sciences Acquire NewLink Genetics?
  17. NewLink Genetics Announces Presentation of Two Abstracts at ASCO
  18. NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : April 20, 2017
  19. Morgan Stanley Ups Incyte Target to $150
  20. The IDO-Inhibitor Race Is On to Improve Cancer Treatment

SEC Filings

  1. 8-K - Current report 17853509
  2. 8-K - Current report 17852569
  3. 8-K - Current report 17851633
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17817633
  5. 8-K - Current report 17811983
  6. 8-K - Current report 17736257
  7. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17729292
  8. DEF 14A - Other definitive proxy statements 17729280
  9. 8-K - Current report 17700121
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17667463